1Department of Pathology, Miao-Li General Hospital, Miaoli City, Taiwan.
2Department of Surgery, Miao-Li General Hospital, Miaoli City, Taiwan.
3Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan.
4Department of Pathology, Taipei Medical University, Taipei, Taiwan.
© 2014 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case No. | Sex/Age (yr) | Site | Size (cm) |
Immunohistochemistry |
EBER | Tx | Outcome (yr) | Reference | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD21 | CD23 | CD35 | CNA.42 | Other | LMP1 | ||||||||
1 | M/70 | Spleen | 5.5 | ND | ND | ND | ND | FDC+ | ND | + | Surgery | NR | Arber et al. [7] |
SMA- | |||||||||||||
2 | F/68 | Liver | 12 | + | ND | + | ND | R4/23+ | + | + | Surgery | NR | Selves et al. [8] |
CT | |||||||||||||
3 | F/35 | Liver | 20 | + | - | + | ND | R4/23+ | + | + | Surgery | Recurrence | Shek et al. [9] |
SMA+ | NED, 2.5 | ||||||||||||
4 | M/37 | Liver | 15 | + | + | + | ND | ND | + | Surgery | NED, 2 | Shek et al. [10] | |
5 | F/19 | Liver | 12 | -/+a | - | -/+a | + | HHF-35+ | +/- | + | Surgery | NED, 3.5 | Cheuk et al. [3] |
6 | F/56 | Liver | 15 | +a | + | +a | + | HHF-35- | + | + | Surgery | Recurrence, alive | Cheuk et al. [3] |
with disease, 4.5 | |||||||||||||
7 | F/40 | Liver | 12.5 | -/+a | - | -/+a | + | HHF-35- | + | + | Surgery | Recurrence, 9 | Cheuk et al. [3] |
8 | F/49 | Liver | 4.2 | +a | + | +a | + | +/- | + | Surgery | NED, 0.75 | Cheuk et al. [3] | |
9 | M/37 | Liver | 15 | +a | +/- | +a | + | HHF-35+/- | - | + | Surgery | NED, 3.5 | Cheuk et al. [3] |
10 | F/35 | Liver | 20 | +* | + | +* | + | HHF-35+/- | +/- | + | Surgery | Recurrence | Cheuk et al. [3] |
DOD, 7.9 | |||||||||||||
11 | F/31 | Liver | 15 | -/+a | - | -/+a | + | HHF-35+/- | - | + | Surgery | NED, 5 | Cheuk et al. [3] |
12 | F/58 | Spleen | 22 | +a | - | +a | + | +/- | + | Surgery | NED, 0.3 | Cheuk et al. [3] | |
13 | F/39 | Spleen | 7.5 | +a | + | +a | + | + | + | Surgery | NED, 0.2 | Cheuk et al. [3] | |
14 | F/61 | Spleen | 3.5 | +a | + | +a | + | HHF-35+/- | +/- | + | Surgery | NR | Cheuk et al. [3] |
15 | F/49 | Peripancreas | 9.5 | +a | + | +a | + | HHF-35- | +/- | + | Surgery | NR | Cheuk et al. [3] |
16 | F/51 | Liver | 15 | + | + | - | ND | ND | + | Surgery | NED, 3 | Chen et al. [11] | |
17 | F/57 | Liver | 12 | + | + | - | ND | ND | + | Surgery | NED, 1 | Chen et al. [11] | |
18 | M/54 | Spleen | 12 | + | + | ND | ND | SMA+ | +/- | + | Surgery | NED, 4 | Brittig et al. [12] |
19 | F/77 | Spleen | 11 | ND | ND | ND | + | + | + | Surgery | NED, 3 | Horiguchi et al. [13] | |
20 | F/30 | Liver | 5.5 | + | ND | + | ND | ND | + | Surgery | NED, 2 | Bai et al. [14] | |
21 | F/50 | Spleen | 5 | + | ND | + | + | SMA+ | ND | + | Surgery | NED, 0.3 | Laurent et al. [15] |
22 | F/57 | Liver | 13 | + | + | ND | ND | ND | + | Surgery | NED, 2 | Granados et al. [16] | |
23 | M/45 | Liver | 14.5 | + | + | - | ND | ND | + | Surgery | NED | Li et al. [5] | |
24 | F/78 | Colon | 3.9 | + | + | + | ND | ND | + | Polypectomy | NED, 0.5 | Present case | |
Subtotal (%) | NA | NA | 11/11 (100) | 13/18 (72) | 6/9 (67) | 13/13 (100) | 6/8 (75) | 24/24 (100) | NA | NA | NA |
NACase 1-3 and 11 are reported as inflammatory pseudotumor.
IPT, inflammatory pseudotumor; FDC, follicular dendritic cell; LMP-1, latent membrane protein 1; EBER, Epstein-Barr virus-encoded mRNA; Tx, treatment; M, male; ND, not done; SMA, smooth muscle actin; NR, not recorded; F, female; CT, chemotherapy; NED, no evidence of disease; DOD, die of disease; NA, not applicable.
aStaining results from using combined CD21 and CD35 antibodies. These cases are not included in the calculation for the percentage of markers expressed by IPT-like FDC sarcomas.
Case No. | Sex/Age (yr) | Site | Size (cm) | Immunohistochemistry |
EBER | Tx | Outcome (yr) | Reference | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CD21 | CD23 | CD35 | CNA.42 | Other | LMP1 | ||||||||
1 | M/70 | Spleen | 5.5 | ND | ND | ND | ND | FDC+ | ND | + | Surgery | NR | Arber et al. [7] |
SMA- | |||||||||||||
2 | F/68 | Liver | 12 | + | ND | + | ND | R4/23+ | + | + | Surgery | NR | Selves et al. [8] |
CT | |||||||||||||
3 | F/35 | Liver | 20 | + | - | + | ND | R4/23+ | + | + | Surgery | Recurrence | Shek et al. [9] |
SMA+ | NED, 2.5 | ||||||||||||
4 | M/37 | Liver | 15 | + | + | + | ND | ND | + | Surgery | NED, 2 | Shek et al. [10] | |
5 | F/19 | Liver | 12 | -/+ |
- | -/+ |
+ | HHF-35+ | +/- | + | Surgery | NED, 3.5 | Cheuk et al. [3] |
6 | F/56 | Liver | 15 | + |
+ | + |
+ | HHF-35- | + | + | Surgery | Recurrence, alive | Cheuk et al. [3] |
with disease, 4.5 | |||||||||||||
7 | F/40 | Liver | 12.5 | -/+ |
- | -/+ |
+ | HHF-35- | + | + | Surgery | Recurrence, 9 | Cheuk et al. [3] |
8 | F/49 | Liver | 4.2 | + |
+ | + |
+ | +/- | + | Surgery | NED, 0.75 | Cheuk et al. [3] | |
9 | M/37 | Liver | 15 | + |
+/- | + |
+ | HHF-35+/- | - | + | Surgery | NED, 3.5 | Cheuk et al. [3] |
10 | F/35 | Liver | 20 | +* | + | +* | + | HHF-35+/- | +/- | + | Surgery | Recurrence | Cheuk et al. [3] |
DOD, 7.9 | |||||||||||||
11 | F/31 | Liver | 15 | -/+ |
- | -/+ |
+ | HHF-35+/- | - | + | Surgery | NED, 5 | Cheuk et al. [3] |
12 | F/58 | Spleen | 22 | + |
- | + |
+ | +/- | + | Surgery | NED, 0.3 | Cheuk et al. [3] | |
13 | F/39 | Spleen | 7.5 | + |
+ | + |
+ | + | + | Surgery | NED, 0.2 | Cheuk et al. [3] | |
14 | F/61 | Spleen | 3.5 | + |
+ | + |
+ | HHF-35+/- | +/- | + | Surgery | NR | Cheuk et al. [3] |
15 | F/49 | Peripancreas | 9.5 | + |
+ | + |
+ | HHF-35- | +/- | + | Surgery | NR | Cheuk et al. [3] |
16 | F/51 | Liver | 15 | + | + | - | ND | ND | + | Surgery | NED, 3 | Chen et al. [11] | |
17 | F/57 | Liver | 12 | + | + | - | ND | ND | + | Surgery | NED, 1 | Chen et al. [11] | |
18 | M/54 | Spleen | 12 | + | + | ND | ND | SMA+ | +/- | + | Surgery | NED, 4 | Brittig et al. [12] |
19 | F/77 | Spleen | 11 | ND | ND | ND | + | + | + | Surgery | NED, 3 | Horiguchi et al. [13] | |
20 | F/30 | Liver | 5.5 | + | ND | + | ND | ND | + | Surgery | NED, 2 | Bai et al. [14] | |
21 | F/50 | Spleen | 5 | + | ND | + | + | SMA+ | ND | + | Surgery | NED, 0.3 | Laurent et al. [15] |
22 | F/57 | Liver | 13 | + | + | ND | ND | ND | + | Surgery | NED, 2 | Granados et al. [16] | |
23 | M/45 | Liver | 14.5 | + | + | - | ND | ND | + | Surgery | NED | Li et al. [5] | |
24 | F/78 | Colon | 3.9 | + | + | + | ND | ND | + | Polypectomy | NED, 0.5 | Present case | |
Subtotal (%) | NA | NA | 11/11 (100) | 13/18 (72) | 6/9 (67) | 13/13 (100) | 6/8 (75) | 24/24 (100) | NA | NA | NA |
NACase 1-3 and 11 are reported as inflammatory pseudotumor. IPT, inflammatory pseudotumor; FDC, follicular dendritic cell; LMP-1, latent membrane protein 1; EBER, Epstein-Barr virus-encoded mRNA; Tx, treatment; M, male; ND, not done; SMA, smooth muscle actin; NR, not recorded; F, female; CT, chemotherapy; NED, no evidence of disease; DOD, die of disease; NA, not applicable. Staining results from using combined CD21 and CD35 antibodies. These cases are not included in the calculation for the percentage of markers expressed by IPT-like FDC sarcomas.